Physician profile
Daniel Lee Warren
NPI 1124768296
$1,107.45
in general payments reported to CMS, 2019-2025
12 companies · $320 in 2025
The $320 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $52.79 · 2024: $735 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $257.47 | 2024 | Na |
| Biocomposites INC | $241.37 | 2024-2025 | Stimulan |
| Cerapedics INC. | $160.00 | 2024 | I-Factor Peptide Enhanced Bone Graft |
| Ortho Development Corporation | $148.91 | 2025 | |
| Heraeus Medical, LLC. | $111.34 | 2024 | |
| Kerecis Limited | $72.83 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Ossur Americas, INC. | $26.85 | 2025 | |
| Merck Sharp & Dohme LLC | $21.98 | 2024 | Dificid, Zerbaxa |
| Mallinckrodt Hospital Products INC. | $18.90 | 2023 | Inomax |
| Shionogi INC | $18.29 | 2023 | Fetroja |
| Bayer Healthcare Pharmaceuticals INC. | $15.60 | 2023 | |
| Bioventus LLC | $13.91 | 2024 | Bonescalpel & Sonicone (O.R.) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.